- Home
- CIGL vs KLRS Comparison
CIGL vs KLRS Comparison
Compare CIGL & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- KLRS
- Stock Information
- Founded
- CIGL 1997
- KLRS 2019
- Country
- CIGL Singapore
- KLRS United States
- Employees
- CIGL N/A
- KLRS N/A
- Industry
- CIGL Diversified Commercial Services
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIGL Consumer Discretionary
- KLRS Health Care
- Exchange
- CIGL Nasdaq
- KLRS Nasdaq
- Market Cap
- CIGL 46.7M
- KLRS 46.0M
- IPO Year
- CIGL 2025
- KLRS N/A
- Fundamental
- Price
- CIGL $5.94
- KLRS $4.64
- Analyst Decision
- CIGL
- KLRS Strong Buy
- Analyst Count
- CIGL 0
- KLRS 2
- Target Price
- CIGL N/A
- KLRS $23.00
- AVG Volume (30 Days)
- CIGL 7.8M
- KLRS 670.7K
- Earning Date
- CIGL 01-01-0001
- KLRS 08-13-2025
- Dividend Yield
- CIGL N/A
- KLRS N/A
- EPS Growth
- CIGL N/A
- KLRS N/A
- EPS
- CIGL N/A
- KLRS N/A
- Revenue
- CIGL $10,490,668.00
- KLRS N/A
- Revenue This Year
- CIGL N/A
- KLRS N/A
- Revenue Next Year
- CIGL N/A
- KLRS N/A
- P/E Ratio
- CIGL N/A
- KLRS N/A
- Revenue Growth
- CIGL N/A
- KLRS N/A
- 52 Week Low
- CIGL $1.40
- KLRS $2.14
- 52 Week High
- CIGL $31.06
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- KLRS 81.20
- Support Level
- CIGL N/A
- KLRS $2.37
- Resistance Level
- CIGL N/A
- KLRS $4.90
- Average True Range (ATR)
- CIGL 0.00
- KLRS 0.61
- MACD
- CIGL 0.00
- KLRS 0.19
- Stochastic Oscillator
- CIGL 0.00
- KLRS 45.81
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.